Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | PRKCA | P17252 | 2/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736149 | 0.83 | PLK1 (0.62) | PTK2CDK5MEN1NPC1RAB9A | |
| SCHEMBL4736832 | 0.80 | PIK3CG (0.65) | CDK5MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4737273 | 0.80 | PLK1 (0.53) | PTK2FLT3JAK2PRKCAPRKCD | |
| SCHEMBL4737548 | 0.79 | PLK1 (0.57) | CDK5MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4736537 | 0.79 | CDK5 (0.50) | CDK5MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14172780 | 0.79 | ABL1 (0.47) | PTK2CDK5FLT3JAK2LCK | |
| SCHEMBL4739251 | 0.77 | ABL1 (0.65) | CDK5MEN1KMT2ACDK5R1PRKCA | |
| SCHEMBL4736211 | 0.77 | MEN1 (0.55) | CDK5MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4732923 | 0.77 | CDK5 (0.52) | CDK5MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4734234 | 0.76 | CDK5 (0.46) | CDK5MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| WO-2008065155-A1 | CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | claimed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| JP-2007500179-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | claimed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008065155-A1 | CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | PTK2 2280/4885CDK5 737/4885MEN1 3759/4885 |
| US-20080153822-A1 | Methods of treating pain | OPRL1, ACHE, OPRK1 | PTK2 2820/4885CDK5 2587/4885MEN1 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.